Consensus estimates for Humana's Q1 2026 stand at $39.5 billion in revenue (+22.8% YoY) and $9.97 in EPS (-13.9% YoY), with the stock trading near $215.23 against an average analyst target of $222.09.
Investors are primarily focused on the Benefit Expense Ratio (BER), which is expected to rise to 89.5% due to higher medical utilization and a substantial $3.5 billion headwind from reduced Medicare Advantage Star Ratings.
The company is navigating a critical multi-year recovery plan intended to stabilize margins after regulatory payment pressures and rising costs severely impacted performance in previous fiscal years. This earnings report is a vital test of management’s ability to execute its "margin over membership" strategy amidst ongoing structural industry challenges.